Bentley University study on Inflation Reduction Act

📑 The draft implementing act on the joint scientific consultations (JSCs) on medicinal products is now under public consultation. JSCs play an essential role in EU HTA to make sure that the evidence submitted by health technology developers are in alignment with the evidence expectations of EMA and the HTA bodies. Moreover, JSCs have the option to cover non-clinical aspects, such as the concept of economic modelling. 🔗 The source is available in the comments section.

Excited to share new achievement that I have completed successfully World Health Organization course of "Ethics and Review of Interventional Clinical Research" by online platform.This program has enhanced my skills and knowledge. This are ethical principles and standards that are essential in clinical research that respects the rights and safety. I gained valuable insights into: 1.Introduction to ethics review of interventional clinical research. 2.The product development pathway. 3.Considerations in study design. 4.Identify key ethical issues associated with different phases of clinical research Thankful to the World Health Organization for making this training accessible to all and for emphasizing the importance of ethical practices in clinical research.This knowledge will be invaluable as I continue to contribute to responsible and impactful research in the healthcare and pharmaceutical fields. #Ethics #ClinicalResearch #clinicaltrials World Health Organization

Thoughts on this? >> Requiem for odds ratios? >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #healthcare #productmarketing #pharmaceutical

The of amount of money and effort put into scientific advancement such as clinical studies is related to the the financial expectations for a successfully developed patented invention. Here we consider the current state of evidence and what information is needed to understand policy decisions that will influence which medicines and vaccines are studied, with Sandra B. of the Information Technology and Innovation Foundation https://lnkd.in/dFqPrhHk

On behalf of the Elsevier Life Sciences team, we wish you a year full of success, innovation, and breakthroughs! As we embrace 2025, we are dedicated to empowering life sciences professionals to tackle challenges and accelerate innovation across the DMTA cycle, regulatory approvals, drug repurposing, and pharmacovigilance. 🚀 Reaxys: Your chemistry powerhouse for the entire DMTA cycle, from designing novel compounds and optimizing synthesis routes to understanding SAR and accelerating decision-making. 🔬 Embase: Supporting critical pharmacovigilance with extensive biomedical indexing. 📊 PharmaPendium: Enhancing regulatory success with access to FDA and EMA data. 🧬 EmBiology: Simplifying pathway analysis and disease understanding for informed decisions. 🤖 SciBite: Transforming data into insights with semantic AI technology. 📚 ScienceDirect & our rich journal portfolio: Delivering trusted, peer-reviewed content to inspire innovation. Let’s make 2025 the year of faster, smarter drug discovery and safer, better therapies. Together, we can turn complex challenges into meaningful progress. Here’s to collaboration, growth, and impact! 🎉 #HappyNewYear2025 #LifeSciences #DrugDiscovery #DMTA #RegulatoryApproval #DrugRepurposing #Pharmacovigilance #Innovation

Today the FDA launched its new Center for Real-World Evidence Innovation (CCRI) program designed to coordinate, advance, and promote the use of real-world data (RWD) and real-world evidence (RWE) in regulatory decision-making across Center for Drug Evaluation and Research (CDER). Focus areas include: 1. Scientific Review and Policy 2. Outreach and Engagement 3. Regulatory Science Initiatives 4. Knowledge Management For more information visit https://lnkd.in/gsBsfh5j

At Ancillarie, we are committed to harnessing the full potential of statistical analysis to revolutionize healthcare delivery. By leveraging advanced analytics techniques, predictive modeling, and data visualization tools, we can uncover actionable insights that drive innovation, enhance efficiency, and ultimately, save lives.   As we embark on this journey, I encourage each of you to embrace the power of statistical analysis in your respective roles. Let's collaborate, innovate, and leverage data-driven insights to transform healthcare delivery and make a meaningful impact on the lives of our patients.   Together, we have the opportunity to shape the future of healthcare through the strategic application of statistical analysis. Let's seize this opportunity and pave the way for a healthier, more vibrant tomorrow. #statisticalanalysis #predictivemodelling #data #clincialtrials #healthcare #datavisualization

Granted, I'm still rather new to the field, but I keep hearing talks from biotechs and even major pharma companies struggling with compound prioritization and lead selection. Each program has its own criteria, so the decision algorithm you use has to be customizable, but standardized for that program. I have been surprised that drug developers haven't more widely employed a technique used throughout other industries for similar decision making: Multi-Criteria Decision Analysis. There are various related algorithms, but here we (really great work by Rafał Bachorz) demonstrate the use of two for compound prioritization AND compound design. The paper is freely available. https://lnkd.in/gyfvagDA We have it integrated into ADMET Predictor for compound prioritization AND into our AI-driven Drug Design platform, but even if you don't use our software, you should consider implementing MCDA in your workflow.

In today’s data-driven world, the ability to turn raw information into actionable insights is the cornerstone of progress. At Ancillarie, we understand that data is more than just numbers—it’s a powerful narrative that, when unlocked, can drive decisions, innovation, and impact. Why Insights Matter Every dataset tells a story. Whether it’s clinical trial results, safety reports, or operational metrics, the insights we derive guide the decisions that shape patient care, compliance, and business outcomes. But transforming data into insights requires more than tools; it requires vision, expertise, and precision. Our Approach At Ancillarie, we combine cutting-edge technologies with deep domain expertise to ensure data is not just managed but maximized. Through robust statistical programming, advanced data visualization, and seamless CDISC implementation, we empower our clients to: ▶️ Identify trends and anomalies in real time. ▶️ Enhance the efficiency of clinical trials. ▶️ Drive informed, patient-centric decisions. Building a Data-Inspired Future As we look ahead, the role of data in shaping healthcare and life sciences will only grow. Our commitment is to stay at the forefront of this transformation—leveraging innovative approaches to ensure our clients are equipped with insights that drive meaningful progress. Data is the foundation, but insights are the power. Together, let’s transform complexity into clarity and pave the way for a brighter, more informed future. #data #innovation #privacy #mapping #implementation ancillarie N-Cillarie N-Cillarie.TataTel N-Cillarie career development and training Cipla SUN PHARMA MACLEODS PHARMACEUTICALS LTD. Encube Ethicals Alkem Laboratories Ltd. ViaLase, Inc Jasper Therapeutics Eloisa R. Sujatha Sitaraman PhD Pranab Pillai mahendra kalantri Sameer Leekha Shreekant Karmarkar BHAVIK DESAI Jas Johal, MBA

I am happy to share that I have obtained a new certification :Good clinical practice from National institute of drug abuse #clinicaltrial #Research #Goodclinicalpractice